Dissecting the Efficacy and Immunogenicity of TLR7 Agonist–Antibody Conjugates through the Lens of Fc Effector Function, Conjugation Strategies, and Linker Cleavability
Journal of Medicinal Chemistry · 11.12.2025 · 68 (23) · 24968-24985
DOI: 10.1021/acs.jmedchem.5c01908 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 24.11.2025. Verfasst von Siteng Fang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Pharmaceutical Sciences, Binghamton University, PO Box 6000, Binghamton, New York 13902-6000, United States. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Immunoconjugates, Immunoglobulin Fc Fragments. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences, Heidelberg Pharma AG.
Abstract (Originalsprache)
The advent of immuno-oncology therapeutics has given rise to antibody-drug conjugates (ADC) designed to selectively activate pattern recognition receptors such as Toll-Like Receptors (TLRs). In contrast to classical ADC technology, these Immune Stimulating Antibody Conjugates (ISACs) are widely reported to rely on Fcγ-mediated uptake and noncleavable linkers. Herein, we systematically study the impact of Fc effector function, linker cleavability, and conjugation strategy on the efficacy and immunogenicity of a series of TLR7 agonist-based ISACs. We demonstrate that the combination of FcγR-ablation and incorporation of a cleavable linker results in increased stimulation of myeloid cells, enhanced efficacy, and improved tolerability as compared to traditional ISAC designs. Interestingly, we found that all ISAC designs exhibited evidence of antidrug-antibody (ADA) induction. We found that the combination of a cleavable linker, a highly permeable TLR7 agonist payload, and ablation of FcγR binding results in ISACs that exhibit particularly favorable properties for continued development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University, PO Box 6000, Binghamton, New York 13902-6000, United States.
ORCID-Profile: Tracy A Brooks, L Nathan Tumey
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
- Heidelberg Pharma AG
Zitieren
APA
Fang, S., Benjamin, S. R., Wu, L., Rahman, M. A., Elder, K. K., Ojo, V. T., Zhang, T., Brooks, T. A., & Tumey, L. N. (2025). Dissecting the Efficacy and Immunogenicity of TLR7 Agonist–Antibody Conjugates through the Lens of Fc Effector Function, Conjugation Strategies, and Linker Cleavability. Journal of Medicinal Chemistry, 68(23), 24968-24985. https://doi.org/10.1021/acs.jmedchem.5c01908
Vancouver
Fang S, Benjamin SR, Wu L, Rahman MA, Elder KK, Ojo VT, et al. Dissecting the Efficacy and Immunogenicity of TLR7 Agonist–Antibody Conjugates through the Lens of Fc Effector Function, Conjugation Strategies, and Linker Cleavability. Journal of Medicinal Chemistry. 2025;68(23):24968-24985. doi:10.1021/acs.jmedchem.5c01908
BibTeX
@article{Fang2025,
author = {Fang, Siteng and Benjamin, Samantha R and Wu, Lina and Rahman, Mohammad Asikur and Elder, Kayla K and Ojo, Victor T and Zhang, Tao and Brooks, Tracy A and Tumey, L Nathan},
title = {Dissecting the Efficacy and Immunogenicity of TLR7 Agonist–Antibody Conjugates through the Lens of Fc Effector Function, Conjugation Strategies, and Linker Cleavability},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {23},
pages = {24968--24985},
doi = {10.1021/acs.jmedchem.5c01908}
}
EUVIMED